What this means
The trial checks how long treated red blood cells last after being given back. It has not reported results yet, so it cannot show whether the treatment works.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 18 and over
- Where
- 2 sites, including Ohio, Virginia
The science
- Registered title
- A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1
- Trial ID
- NCT07015437 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Healthy Subjects
- What is tested
- INTERCEPT Blood System for RBCs, Infusion of autologous radiolabeled RBCs
- Sponsor
- Cerus Corporation
- Ages
- 18 Years to no maximum
- Dates
- First posted Jun 11, 2025 · updated Sep 21, 2026
Registry summary
The objective of this trial is to assess the post-infusion viability of INTERCEPT RBCs by measuring the 24-hour post-infusion recovery and lifespan of autologous RBCs prepared with the INTERCEPT Blood System for RBC with AS-1 after 35 days post collection storage in comparison to untreated AS-1 RBCs stored for 35 days.
Sites (2)
- Hoxworth Blood Center, Cincinnati, Ohio, United States
- American Red Cross Research Laboratory, Norfolk, Virginia, United States